Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted intravenous melphalan for AL amyloidosis
ACTRN12605000795695Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan, dexamethasone and filgrastim in light-chain amyloidosis (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Hematologic response rate. Started Jun 2006; status: completed.
02
Drugs
melphalandexamethasonefilgrastim
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ACTRN12605000795695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000795695.